Clinical trial · Interventional
Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
NCT02929615CI-TRIAL-00024254unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to research the standard and individualized treatment model for relapse and refractory lymphatic system malignant tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hematopoietic stem cell transplantation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment group
- interventionNames
- Other: Hematopoietic stem cell transplantation
Primary outcomes (4)
- measure
- overall response rate
- timeFrame
- 2 years after treatment
- measure
- complete response
- timeFrame
- 2 years after treatment
- measure
- progression-free survival
- timeFrame
- 2 years after treatment
- measure
- overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with relapse and refractory lymphoma and multiple myeloma. 2. At least 1 measurable lesions and its size≥15mm. 3. Patients ≤65 years，no limitations for both gender. 4. ECOG score is 0-1. 5. Life expectancy≥3 months. 6. LVEF≥ 55%; Peripheral blood: WBC ≥ 3.5×10(9)/L,neutrophil ≥1.5×10(9)/L, PLT≥75×109/L，Hb≥90g/L; Renal function: Cr≤2.0×UNL; Liver function: BIL≤2.0×UNL，ALT/AST≤2.5×UNL; 7. Written informed consent are acquired. Exclusion Criteria: 1. Previously received stem cell transplantation. 2. Women with pregnant, lactating or not to take contraceptive measures. 3. Severe acute infection or suppurative and chronic infection that wound not healing. 4. Severe heart failure. 5. Suffering from mental disorders and poor compliance. 6. Other situations that investigators consider as contra-indication for this study.
References
Publications (0)
Data not yet available
No reference posted for this study.